Home / Clinics / Stem Cell Therapy
Open a Stem Cell Clinic Massive Demand. Almost No Compliant Supply.
Patient demand in this category is real and growing. So is FDA enforcement. Most firms selling stem cell clinic builds will hand you a supplier and wish you luck. ACG builds the regulatory foundation first, because the operators still standing in five years will be the ones who did.
Book a Strategy CallWhat the Numbers Actually Show
The global stem cell therapy market is valued in the range of $20 billion to $23 billion in 2026, with projected compound annual growth of roughly 12 to 13 percent through 2035. North America holds the majority share, and by therapeutic application, musculoskeletal is the single largest segment, which is why joint and orthopedic-adjacent programs are the most common entry point for a new clinic.
Be careful with the headline numbers you see elsewhere. Published estimates for this category range from under $1 billion to more than $23 billion for the same year, because research firms define the market differently. Some count only approved, commercialized therapies. Others count the entire cell therapy sector. Anyone quoting you one number without telling you which definition they used is selling, not informing.
The demand is not the hard part. The hard part is building a clinic that is still open, still advertising, and still compliant three years from now. That is a much smaller group than the number of people currently entering this category.
Sources: Precedence Research and Coherent Market Insights, 2026. Estimates vary by market definition. Local demand varies by market.
What a Stem Cell Clinic Actually Offers Patients
Clinics in this category build service lines around cellular and tissue-based products, usually alongside adjacent regenerative offerings. The service menu below reflects how these clinics are commonly structured. It is not a statement of clinical outcomes, and nothing here should be read as a claim about what any product does for any patient. That determination belongs to your Medical Director and to the evidence.
Musculoskeletal is the largest application segment in this category and the most common anchor service line for a new clinic. See our Joint and Musculoskeletal clinic model for the full standalone build.
Commonly built alongside PRP and other regenerative offerings in the same treatment room. Our Hair Regeneration page covers the standalone clinic economics and patient model.
A high-margin, high-retention category that many operators pair with a cellular service line. See our Sexual Wellness clinic page for the full standalone model.
Cellular offerings are frequently positioned inside a broader longevity practice with biomarker panels, hormone optimization, and IV therapy.
Platelet-rich plasma prepared and returned to the same patient in a single procedure sits in a different regulatory posture than allograft tissue products. Many clinics start here for that reason.
A fast-growing product category and an active FDA enforcement target. Labeling a product an exosome does not exempt it from the HCT/P framework. Read the compliance section below before you build this line.
Imaging, lab panels, and structured intake and consent workflows. In a category under this much scrutiny, documentation is not paperwork, it is your defense.
Every clinical decision, protocol, and product selection runs through a licensed physician. ACG introduces clients to vetted Medical Directors across all 50 states.
The 361 vs 351 Question Most Operators Cannot Answer
Human cells and tissues are regulated by the FDA under 21 CFR Part 1271. A product that meets every criterion in section 1271.10(a) is regulated solely under Section 361 of the Public Health Service Act and requires no premarket approval. A product that misses even one of those criteria is regulated under Section 351, which means it is a biological product requiring an approved license before it can be lawfully marketed.
Homologous use is where most products fail the test. It is not optional, it is a mandatory criterion. A product must perform the same basic function in the recipient that it performed in the donor. That single requirement is the reason the FDA has issued warning letters to umbilical and birth-tissue suppliers whose products were being marketed for uses the agency considers non-homologous.
The FDA's period of enforcement discretion for these products ended on May 31, 2021. The agency's stated position is that anyone marketing a product that requires premarket review without it does so at their own risk. And the clinic administering the product carries exposure even when it did not manufacture it.
This is the section every other consultant skips. We lead with it. Not because it is comfortable, but because the clinics that get this wrong do not get a second chance, and we are not interested in launching a business that gets shut down.
Before a lease is signed, ACG works through the 361 vs 351 question with you, your Medical Director, and your counsel. Every downstream decision depends on this answer.
Minimal manipulation. Homologous use. No combination with another article. No systemic effect or dependence on the metabolic activity of living cells, unless autologous or from a close blood relative. All four, not three.
ACG helps you press suppliers for the documentation that actually matters, and to recognize the answers that should end the conversation. A supplier's marketing claim is not a regulatory determination.
Intended-use claims help determine how a product is classified. Copy that promises what a product does for a condition can move that product into a category requiring FDA approval. Your website is part of your compliance posture.
Protocols, product selection, and patient consent are reviewed and formally approved by a licensed physician before first patient. ACG coordinates that relationship across all 50 states.
Paid platforms restrict this category aggressively. Organic search and owned content are the durable acquisition channels here, and ACG builds that infrastructure from day one.
Why This Category Builds Durable Clinics
This is a cash-pay category. No insurance billing cycles, no reimbursement negotiations, no revenue delay. Patients pay at the point of service, and protocols in this space are typically structured as multi-visit programs rather than one-off appointments.
One fee. One engagement. Everything included. No upsells, no ongoing royalties, no franchise dependency. You own the clinic, the brand, and the equity.
Cash-Pay
No insurance billing, no reimbursement cycles, no margin erosion from third-party payers.
Required
ACG coordinates the clinical infrastructure. You own and operate the business.
Launched
Across all 50 states, over 30+ years of combined operational history.
Launch Window
From keys received, market and regulatory conditions permitting.
Answers Before
You Open.
This category rewards operators who understand the regulatory picture and punishes the ones who do not. The answers below are direct, including the uncomfortable ones.
If something isn't covered here, that's what the consultation is for. No pressure, no pitch.
View All FAQsWhat is the difference between a 361 and a 351 product?
Are umbilical or Wharton's jelly products automatically 361 compliant?
What does "homologous use" actually mean?
Can my marketing copy affect how my product is regulated?
Do I need to be a physician to own a stem cell clinic?
What other service lines pair well with this clinic type?
Can I advertise a stem cell clinic on Meta and Google?
What revenue per patient is realistic in this category?
Build It Right,
Or Do Not Build It.
Book a free 30-minute strategy call. ACG will walk you through the opportunity in your specific market, the classification question, the supplier picture, and what the process looks like from first conversation to open doors.
Book a Strategy CallFree 30-minute call · No pitch · ACG works with a select number of clients at any given time